Table 1.

Patient characteristics at trial entry

Baseline characteristicsN (%) (N = 58)
Age, y  
 Median (range) 52 (20-68) 
Sex  
 Female 23 (40%) 
 Male 35 (60%) 
Blood group  
 A 25 (43%) 
 O 24 (41%) 
 B 6 (10%) 
 AB 3 (5%) 
Ethnicity  
 White 40 (69%) 
 Asian or Asian British 10 (17%) 
 Mixed race 4 (7%) 
 Black or Black British 3 (5%) 
 Chinese 1 (2%) 
Performance status  
 70% 2 (3%) 
 80% 5 (9%) 
 90% 27 (47%) 
 100% 24 (41%) 
Primary diagnosis  
 Acute myeloid leukemia 27 (47%) 
 Acute lymphoblastic leukemia 7 (12%) 
 Non-Hodgkin (follicular lymphoma, B-cell lymphoma) 7 (12%) 
 Myelodysplasia syndrome 7 (12%) 
 Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) 3 (5%) 
 Hodgkin lymphoma 3 (5%) 
 Acute undifferentiated leukemia 1 (2%) 
 Chronic myeloid leukemia 1 (2%) 
 Multiple myeloma 1 (2%) 
 Primary myelofibrosis transformed to acute myeloid leukemia 1 (2%) 
Disease status at registration  
 Complete response 46 (79%) 
 Partial response 8 (14%) 
 Progression/relapse 2 (3%) 
 Accelerated phase 1 (2%) 
 Unknown 1 (2%) 
Comorbidity index  
 0 28 (48%) 
 1 12 (21%) 
 2 8 (14%) 
 3+ 9 (16%) 
 Not reported 1 (2%) 
Lines of prior treatment  
 0 1 (2%) 
 1 17 (29%) 
 2 26 (45%) 
 3+ 14 (24%) 
Baseline characteristicsN (%) (N = 58)
Age, y  
 Median (range) 52 (20-68) 
Sex  
 Female 23 (40%) 
 Male 35 (60%) 
Blood group  
 A 25 (43%) 
 O 24 (41%) 
 B 6 (10%) 
 AB 3 (5%) 
Ethnicity  
 White 40 (69%) 
 Asian or Asian British 10 (17%) 
 Mixed race 4 (7%) 
 Black or Black British 3 (5%) 
 Chinese 1 (2%) 
Performance status  
 70% 2 (3%) 
 80% 5 (9%) 
 90% 27 (47%) 
 100% 24 (41%) 
Primary diagnosis  
 Acute myeloid leukemia 27 (47%) 
 Acute lymphoblastic leukemia 7 (12%) 
 Non-Hodgkin (follicular lymphoma, B-cell lymphoma) 7 (12%) 
 Myelodysplasia syndrome 7 (12%) 
 Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) 3 (5%) 
 Hodgkin lymphoma 3 (5%) 
 Acute undifferentiated leukemia 1 (2%) 
 Chronic myeloid leukemia 1 (2%) 
 Multiple myeloma 1 (2%) 
 Primary myelofibrosis transformed to acute myeloid leukemia 1 (2%) 
Disease status at registration  
 Complete response 46 (79%) 
 Partial response 8 (14%) 
 Progression/relapse 2 (3%) 
 Accelerated phase 1 (2%) 
 Unknown 1 (2%) 
Comorbidity index  
 0 28 (48%) 
 1 12 (21%) 
 2 8 (14%) 
 3+ 9 (16%) 
 Not reported 1 (2%) 
Lines of prior treatment  
 0 1 (2%) 
 1 17 (29%) 
 2 26 (45%) 
 3+ 14 (24%)